We are lowering our full-year 2022 revenue guidance to $275 million. Our revised guidance is based on engagement marketing as a percentage of revenue of approximately 42% and implies our RAEM will be $160 million for full-year 2022. Based on the revised revenue and RAEM guidance, we expect to achieve a full year 2022 Adjusted EBITDA margin of approximately -56%.
Cue Biopharma And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
